Early beginnings
What Georges Köhler and César Milstein started in 1975 went on to become a multi-billion dollar market in lifechanging antibody therapies and powerful reagents used to understand key biological functions.
With at least 30 new monoclonal antibody therapies expected to be approved by 2025, antibody production remains key to delivering modern treatments.
Today, Envigo delivers: Monoclonal and polyclonal antibody production, hybridoma development, Antibody purification, and mouse antibody production (MAP) testing
History, strategies & challenges
Download the infographic series
Get the first in a series of infographics, charting the history, production strategies and technology challenges faced when producing antibodies for research and manufacture. These resources provide insights collated from Envigo’s long history in antibody production, with quick reference production strategies and useful reminders of the challenges commonly faced by researchers and production engineers.
